Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2022

Open Access 01-12-2022 | Fibromyalgia | Protocol

Effectiveness of multicomponent treatment in patients with fibromyalgia: protocol for a systematic review and meta-analysis

Authors: Felipe Araya-Quintanilla, Héctor Gutiérrez-Espinoza, Jorge Fuentes, Fernanda Prieto-Lafrentz, Leonardo Pavez, Carlos Cristi-Montero, Iván Cavero-Redondo, Celia Álvarez-Bueno

Published in: Systematic Reviews | Issue 1/2022

Login to get access

Abstract

Background

The purpose of this protocol is to provide a new systematic review with meta-analysis using the current methodology to compare the effectiveness of multicomponent treatment versus other interventions for patients with fibromyalgia.

Methods

This protocol conforms to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) and the recommendations of the Cochrane Collaboration Handbook. An electronic search will be conducted in MEDLINE, EMBASE, Web of Science, Cochrane CENTRAL, LILACS, CINAHL, and PEDro, from inception until April 2022. There will be no language restrictions. The Cochrane Collaboration tool for assessing the risk of bias (RoB2) will be used. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) scale will be used to evaluate the strength of the evidence. The Hartung-Knapp-Sidik-Jonkman random effects or Mantel-Haenszel fixed effects methods will be used, depending on the heterogeneity, to compute a pooled estimate of the mean difference (MD) or standardized mean difference (SMD) and respective 95% confidence intervals for clinical outcomes.

Discussion

This systematic review will synthesize evidence on the effectiveness of multicomponent treatment in patients with fibromyalgia and could add important evidence in the treatment of FM to improve clinical practice and decision-making/actions in this field. This new systematic review will try to show the effects of multicomponent treatment by type (endurance, resistance, stretching, or mind-body exercises [pilates or taichi]) and intensity (light, moderate, moderate-to-vigorous, vigorous) of exercise in patients with FM. The results will be disseminated by publication in a peer-reviewed journal. Ethics approval will not be needed because the data used for this systematic review will be obtained from individual trials and there will be no concerns about privacy. However, if we identify ethical issues during the development of the systematic review, these findings will be reported in the discussion of the study.

Systematic review registration

PROSPERO CRD42020142082.
Literature
1.
Wolfe F, Clauw DJ, Fitzcharles M, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113–22.CrossRefPubMed
2.
Borchers AT, Gershwin ME. Fibromyalgia: a critical and comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):100–51.CrossRefPubMed
3.
4.
Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017;57(4):356–63.CrossRefPubMed
5.
Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil. 2005;27:685–94.CrossRefPubMed
6.
Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31:1391–8.PubMed
7.
Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7:1027–39.CrossRefPubMed
8.
Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–41.CrossRefPubMed
9.
Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain. 2010;14(1):5–10.CrossRefPubMed
10.
Nüesch E, Häuser W, Bernardy K, et al. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72:955–62.CrossRefPubMed
11.
Han C, Lee SJ, Lee SY, Seo HJ, Wang SM, Park MH, et al. Available therapies and current management of fibromyalgia: focusing on pharmacological agents. Drugs Today (Barc). 2011;47:539–57.CrossRef
12.
Arnold LM, Clauw DJ. Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med. 2017;129(7):709–14.CrossRefPubMed
13.
Atzeni F, Gerardi MC, Masala IF, Alciati A, Batticciotto A, Sarzi-Puttini P. An update on emerging drugs for fibromyalgia treatment. Expert Opin Emerg Drugs. 2017;22(4):357–67.CrossRefPubMed
14.
Häuser W, Bernardy K, Arnold B, Offenbächer M, Schiltenwolf M. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Care Res. 2009;61(2):216–24.CrossRef
15.
Saral I, Sindel D, Esmaeilzadeh S, Sertel-Berk HO, Oral A. The effects of long- and short-term interdisciplinary treatment approaches in women with fibromyalgia: a randomized controlled trial. Rheumatol Int. 2016;36(10):1379–89.CrossRefPubMed
16.
Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med. 2013;2013:485272.PubMedPubMedCentral
17.
Busch AJ, Webber SC, Richards RS, Bidonde J, Schachter CL, Schafer LA, et al. Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev. 2013;12:CD010884.
18.
Bernardy K, Klose P, Busch AJ, et al. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;9:CD009796.
19.
Van Den Houte M, Luyckx K, Van Oudenhove L, Bogaerts K, Van Diest I, De Bie J, et al. Differentiating progress in a clinical group of fibromyalgia patients during and following a multicomponent treatment program. J Psychosom Res. 2017;98:47–54.CrossRef
20.
Arnold B, Häuser W, Arnold M, et al. Multicomponent therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz. 2012;26:287–90.CrossRefPubMed
21.
Thieme K, Mathys M, Turk DC. Evidenced-based guidelines on the treatment of fibromyalgia patients: are they consistent and if not, why not? Have effective psychological treatments been overlooked? J Pain. 2017;18(7):747–56.CrossRefPubMed
22.
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromialgia. Ann Rheum Dis. 2017;76(2):318–28.CrossRefPubMed
23.
24.
Schiltenwolf M, Eidmann U, Köllner V, Kühn T, Offenbächer M, Petzke F, et al. Multimodal therapy of fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):285–8.CrossRefPubMed
25.
Arnold B, Häuser W, Bernardy K, Brückle W, Friedel E, Köllner V, et al. Multicomponent therapy for treatment of fibromyalgia syndrome. Schmerz. 2008;22(3):334–8.CrossRefPubMed
26.
Skelly AC, Chou R, Dettori JR, Turner JA, Friedly JL, Rundell SD, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review. Rockville: Agency for Healthcare Research and Quality (US); 2018. Report No.: 18-EHC013-EF
27.
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRefPubMedPubMedCentral
28.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. 2021. Available from www.​training.​cochrane.​org/​handbook.
29.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10.CrossRef
30.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(366):l4898.CrossRef
31.
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.CrossRefPubMed
32.
Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE Working Group. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126–35.CrossRefPubMed
33.
IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;18(14):25.CrossRef
34.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta–analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
35.
Sterne JA, Egger M, Smith GD. Systematic reviews in healthcare: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101–5.CrossRefPubMedPubMedCentral
36.
Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int. 2017;37(9):1527–39.CrossRefPubMed
37.
Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018;2(2):CD010585.PubMed
38.
Serrat M, Sanabria-Mazo JP, Almirall M, Musté M, Feliu-Soler A, Méndez-Ulrich JL, Sanz A, Luciano JV. Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioral Therapy, and Mindfulness in Patients With Fibromyalgia (FIBROWALK Study): A Randomized Controlled Trial. Phys Ther. 2021;101(12):pzab200.
39.
Pérez-Aranda A, Feliu-Soler A, Montero-Marín J, García-Campayo J, Andrés-Rodríguez L, Borràs X, et al. A randomized controlled efficacy trial of mindfulness-based stress reduction compared with an active control group and usual care for fibromyalgia: the EUDAIMON study. Pain. 2019;160(11):2508–23.CrossRefPubMed
40.
Salaffi F, Ciapetti A, Gasparini S, Atzeni F, Sarzi-Puttini P, Baroni M. Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia. Clin Exp Rheumatol. 2015;33(1 Suppl 88):S93–101.PubMed
41.
Bourgault P, Lacasse A, Marchand S, Courtemanche-Harel R, Charest J, Gaumond I, et al. Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: a mixed-methods randomized controlled trial. PLoS One. 2015;10(5):e0126324.CrossRefPubMedPubMedCentral
42.
Martín J, Torre F, Padierna A, Aguirre U, González N, Matellanes B, et al. Impact of interdisciplinary treatment on physical and psychosocial parameters in patients with fibromyalgia: results of a randomised trial. Int J Clin Pract. 2014;68(5):618–27.CrossRefPubMed
43.
Serrat M, Almirall M, Musté M, Sanabria-Mazo JP, Feliu-Soler A, Méndez-Ulrich JL, et al. Effectiveness of a multicomponent treatment for fibromyalgia based on pain neuroscience education, exercise therapy, psychological support, and nature exposure (NAT-FM): a pragmatic randomized controlled trial. J Clin Med. 2020;9(10):3348.CrossRefPubMedCentral
44.
Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347–68.CrossRefPubMed
45.
Worrel L, Krahn L, Sletten C, Pond G. Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. Mayo Clin Proc. 2001;76:384–90.CrossRefPubMed
Metadata
Title
Effectiveness of multicomponent treatment in patients with fibromyalgia: protocol for a systematic review and meta-analysis
Authors
Felipe Araya-Quintanilla
Héctor Gutiérrez-Espinoza
Jorge Fuentes
Fernanda Prieto-Lafrentz
Leonardo Pavez
Carlos Cristi-Montero
Iván Cavero-Redondo
Celia Álvarez-Bueno
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2022
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-022-01944-1

Other articles of this Issue 1/2022

Systematic Reviews 1/2022 Go to the issue

Protocol

Social determinants of health and cancer screening implementation and outcomes in the USA: a systematic review protocol

Protocol

The development and education of a workforce in childhood cancer services in low- and middle-income countries: a scoping review protocol

Protocol

Impact of health system engagement on the health and well-being of people who use drugs: a realist review protocol

Methodology

Machine learning reduced workload for the Cochrane COVID-19 Study Register: development and evaluation of the Cochrane COVID-19 Study Classifier

Protocol

Public sector implementation strategies to approach the judicialization of health care: a systematic review protocol

Protocol

Synthesising the existing evidence for non-pharmacological interventions targeting outcomes relevant to young people with ADHD in the school setting: systematic review protocol